Insulet (PODD) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Insulet (PODD) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 17.54% |
| 10 | Insulet | 10.18 Bn | 9.64 Bn | 562.60 Mn | 51.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.54% |
| Mar 31, 2026 | 56.43% |
| Dec 31, 2025 | 81.53% |
| Sep 30, 2025 | 166.12% |
| Jun 30, 2025 | 38.26% |
| Mar 31, 2025 | 8.49% |
| Dec 31, 2024 | 51.08% |
| Sep 30, 2024 | 83.22% |
| Jun 30, 2024 | 112.12% |
| Dec 31, 2023 | 100.39% |
| Sep 30, 2023 | 64.78% |
| Jun 30, 2023 | 23.77% |
| Mar 31, 2023 | 137.13% |
| Dec 31, 2022 | 50.37% |
| Sep 30, 2022 | -104.08% |
| Jun 30, 2022 | -200.00% |
| Mar 31, 2022 | 84.87% |
| Dec 31, 2021 | 43.41% |
| Sep 30, 2021 | 96.57% |
| Jun 30, 2021 | -145.43% |